PH12015501533A1 - Controlled release formulations of lorazepam - Google Patents

Controlled release formulations of lorazepam

Info

Publication number
PH12015501533A1
PH12015501533A1 PH12015501533A PH12015501533A PH12015501533A1 PH 12015501533 A1 PH12015501533 A1 PH 12015501533A1 PH 12015501533 A PH12015501533 A PH 12015501533A PH 12015501533 A PH12015501533 A PH 12015501533A PH 12015501533 A1 PH12015501533 A1 PH 12015501533A1
Authority
PH
Philippines
Prior art keywords
release
lorazepam
controlled release
release formulations
dosing
Prior art date
Application number
PH12015501533A
Inventor
Douglas A Saltel
Vachon Michael
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015501533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of PH12015501533A1 publication Critical patent/PH12015501533A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Controlled release of lorazepam can provide enhanced dosing options including once daily dosing that provides 24 hour therapeutic effect under steady state conditions. The pharmaceutical composition can provide substantially zero order release and 90 pcnt release within 7 to 12 hours in a pharmaceutical dissolution test. The release can be achieved using polyethylene oxide as a matrix polymer.
PH12015501533A 2013-01-09 2015-07-07 Controlled release formulations of lorazepam PH12015501533A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750792P 2013-01-09 2013-01-09
US201361762836P 2013-02-08 2013-02-08
PCT/US2014/010863 WO2014110248A1 (en) 2013-01-09 2014-01-09 Controlled release formulations of lorazepam

Publications (1)

Publication Number Publication Date
PH12015501533A1 true PH12015501533A1 (en) 2015-10-05

Family

ID=50030512

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015501533A PH12015501533A1 (en) 2013-01-09 2015-07-07 Controlled release formulations of lorazepam

Country Status (16)

Country Link
EP (1) EP2943186A1 (en)
JP (1) JP2016504391A (en)
KR (1) KR20150127037A (en)
CN (1) CN105188682A (en)
AU (1) AU2014205356A1 (en)
BR (1) BR112015016322A8 (en)
CA (1) CA2897313A1 (en)
CL (1) CL2015001921A1 (en)
HK (1) HK1213803A1 (en)
IL (1) IL239778A0 (en)
MX (1) MX2015008757A (en)
PE (1) PE20151431A1 (en)
PH (1) PH12015501533A1 (en)
RU (1) RU2015128914A (en)
SG (1) SG11201505352RA (en)
WO (1) WO2014110248A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078601A (en) 2017-11-01 2020-07-01 엣지몬트 파마슈티칼스 엘엘씨 트러스트 Alcohol-resistant oral pharmaceutical composition of lorazepam

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (en) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
KR850700212A (en) * 1984-03-21 1985-12-26 죠지 드모트 Sustained Release Pharmaceutical Wexel
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
CO5140079A1 (en) * 1998-10-14 2002-03-22 Novartis Ag PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
EP1347748A2 (en) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
CA2448558A1 (en) 2001-07-10 2003-01-23 Teva Pharmaceutical Industries, Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0302017B1 (en) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Sublingual pharmaceutical composition based on a benzodiazepine central receptor agonist
KR100822519B1 (en) * 2005-02-15 2008-04-16 주식회사종근당 Gastric-retentive controlled release mono-matrix tablet

Also Published As

Publication number Publication date
RU2015128914A (en) 2017-02-14
EP2943186A1 (en) 2015-11-18
IL239778A0 (en) 2015-08-31
JP2016504391A (en) 2016-02-12
BR112015016322A2 (en) 2017-07-11
MX2015008757A (en) 2016-02-05
HK1213803A1 (en) 2016-07-15
KR20150127037A (en) 2015-11-16
BR112015016322A8 (en) 2018-01-23
PE20151431A1 (en) 2015-09-23
CN105188682A (en) 2015-12-23
WO2014110248A1 (en) 2014-07-17
SG11201505352RA (en) 2015-08-28
CL2015001921A1 (en) 2015-12-18
AU2014205356A1 (en) 2015-07-30
CA2897313A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
HRP20181364T1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
IN2015DN00544A (en)
HK1203947A1 (en) Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol)
MX2016011290A (en) Lipoic acid choline ester compositions and methods of use.
TN2015000498A1 (en) Modified release formulation
SG10201704712QA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
AU201714443S (en) Pharmaceutical tablet
AU343717S (en) Sticking plaster used for medical purposes
HK1222337A1 (en) Topical composition and carrier for administration of pharmaceutical or cosmetic active ingredients
MX370990B (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
PH12015501533A1 (en) Controlled release formulations of lorazepam
HK1204967A1 (en) Composition containing natural plant extracts as active ingredients, external skin preparation comprising the same, cosmetic preparation comprising the same and pharmaceutical preparation comprising the same
PH12015501534A1 (en) Sustained release formulations of lorazepam
AU343718S (en) Sticking plaster used for medical purposes
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
AU201715165S (en) Pharmaceutical tablet
AU201715163S (en) Pharmaceutical tablet
AR094391A1 (en) LORAZEPAM FORMULATIONS OF SUSTAINED RELEASE
AU343293S (en) Sticking plaster used for medical purposes
AU343716S (en) Sticking plaster used for medical purposes
AU343715S (en) Sticking plaster used for medical purposes
UA99891C2 (en) Methyl-3-(3-r-6-imidazo[1,2-a]pyridine-2-yl)acrylate derivatives and process for the peparation thereof
TH1401007652A (en) Aminotriazolopyridines for use in the treatment of inflammation and its pharmaceutical composition
UA53217U (en) Mask for therapy and general health improvement